Thursday, May 30, 2013: 7:00 PM-8:30 PM
Patient-Reported Outcomes After Fingolimod Switch: Early Consistent Benefit
Mark Cascione, MD, Tampa Neurology Associates;
Neetu Agashivala, MS, Novartis Pharmaceuticals Corporation;
Stanley Li, MS, Minimax Information Services;
Luigi M Barbato, MD, Novartis Pharmaceuticals Corporation;
Edward Kim, MD, MBA, Novartis Pharmaceuticals Corporation
Treatment Selection in Multiple Sclerosis: Results of a Physician Survey
Kristin A Hanson, PharmD, MS, United BioSource Corporation;
Neetu Agashivala, MS, Novartis Pharmaceuticals Corporation;
Karina Raimundo, BPharm, MS, Novartis Pharmaceuticals Corporation;
Edward Kim, MD, MBA, Novartis Pharmaceuticals Corporation;
Sonja M Stringer, MPH, United BioSource Corporation;
Zaneta Balantac, BS, United BioSource Corporation;
Kathleen W Wyrwich, PhD, United BioSource Corporation;
David W Brandes, MS, MD, FAAN, Hope MS Center
Fingolimod Efficacy and Safety vs. Placebo: Phase 3 FREEDOMS II Study
Mark Agius, MD, UC Davis Center for Neuroscience;
Douglas Jeffery, MD, PhD, Cornerstone Healthcare;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Ron Hashmonay, MD, Novartis Pharmaceuticals Corporation;
Allitia DiBernardo, MD, Novartis Pharmaceuticals Corporation
25-Hydroxyvitamin D and MS Activity During Therapy with Interferon Beta-1b
Alberto Ascherio, MD, Harvard University;
Kassandra Munger, ScD, Harvard University;
Claire Simon, ScD, Harvard University;
Ludwig Kappos, MD, University Hospital, Basel Neurology, Basel, Switzerland;
Chris H Polman, MD, VU Medical Center;
Mark Freedman, MD, University of Ottawa;
Hans-Peter Hartung, MD, Heinrich-Heine University, Dusseldorf, Germany;
David Miller, MBChB, MD, FRCP, UCL Institute of Neurology;
Xavier Montalban, MD, Hospital Universitari Vall d’Hebron;
Gilles Edan, MD, CHU-Hôpital Pontchaillou;
Frederik Barkhof, MD, PhD, VU Medical Center;
Rupert Sandbrink, MD, Bayer Pharma AG;
Karl Kochert, MD, Bayer Pharma AG;
Christoph Pohl, MD, University Hospital of Bonn
Natalizumab in Anti-JCV Seronegative Patients with Early MS: STRIVE Study
Roumen Balabanov, MD, Rush University Multiple Sclerosis Center;
Jai Perumal, MD, Judith Jaffe Multiple Sclerosis Center;
Robert J. Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic;
Denise Campagnolo, MD, Biogen Idec Inc.;
Emese Dian, PhD, Biogen Idec Inc.;
Stefan Lanker, PhD, Biogen Idec Inc.;
Jennifer Sun, MSc, Biogen Idec Inc.;
Mary-Jean Fanelli, MD, MBA, Biogen Idec Inc.
A Comparison of 2 Health-Related Quality of Life Measures in Pediatric Demyelination
Austin Sye, BA, Hospital for Sick Children;
E Ann Yeh, MD, Hospital for Sick Children, University of Toronto;
Brenda Banwell, MD, Hospital for Sick Children, University of Toronto;
Christine Till, PhD, C.Psych, Hospital for Sick Children;
Nadine Akbar, PhD Candidate, MSc, University of Toronto
Peginterferon Beta-1a Via Autoinjector in Relapsing Multiple Sclerosis
Peter A Calabresi, MD, FAAN, Johns Hopkins University, Baltimore, MD, USA;
Serena Hung, MD, Biogen Idec Inc;
Ali Seddighzadeh, MD, Biogen Idec Inc;
Shifang Liu, PhD, Biogen Idec Inc;
Bjorn Sperling, MD, Biogen Idec Inc;
Aaron Deykin, MD, Biogen Idec Inc
Depression, Fatigue and Clinical Improvements After Switch To Fingolimod
Mark Agius, MD, UC Davis Center for Neuroscience;
Edward Kim, MD, MBA, Novartis Pharmaceuticals Corporation;
Stanley Li, MS, Minimax Information Services;
Peter Chin, MD, Novartis Pharmaceuticals Corporation;
Ron Hashmonay, MD, Novartis Pharmaceuticals Corporation;
Neetu Agashivala, MS, Novartis Pharmaceuticals Corporation
Joint Commission Disease Specific Care Certification Process for Multiple Sclerosis
Jill M Conway, MD, MA, MSCE, Carolinas Healthcare System;
Lindsey Belt, RN, BSN, Carolinas Healthcare System;
Michael Kaufman, MD, Carolinas Healthcare System;
Linda Moore, NP, EdD, Carolinas Healthcare System;
Marie Moore, NP, Carolinas Healthcare System;
Marlow Price, RN, Carolinas Healthcare System;
Lisa Smart, RN, Carolinas Healthcare System;
Diana Sutton, RN, BSN, Carolinas Healthcare System;
Charlotte Craig, RN, BSN, Carolinas Healthcare System
Improved Quality of Life After Therapy Change to Fingolimod
Heidi Crayton, MD, MS Center of Greater Washington;
Samuel F. Hunter, MD, PhD, Advanced Neurosciences Institute;
Cynthia Huffman, MD, Meridien Research;
Neetu Agashivala, MS, Novartis Pharmaceuticals Corporation;
Lesley Schofield, PhD, Novartis Pharmaceuticals Corporation;
Kevin McCague, MA, Novartis Pharmaceuticals Corporation;
Luigi M Barbato, MD, Novartis Pharmaceuticals Corporation
Alemtuzumab's Effects on Disability Outcomes Occur Early in Care-MS II
Heidi Crayton, MD, MS Center of Greater Washington;
Douglas L Arnold, MD, Montreal Neurological Institute, McGill University, and NeuroRx Research, Montreal, Quebec, Canada;
Jeffrey A Cohen, MD, Cleveland Clinic, Cleveland, OH, USA;
Alasdair J Coles, MD, University of Cambridge, Cambridge, UK;
Christian Confavreux, MD, University Claude Bernard, Lyon, France;
Edward J Fox, MD, MS Clinic of Central Texas, Round Rock, TX, USA;
Hans-Peter Hartung, MD, Heinrich-Heine University, Dusseldorf, Germany;
Eva Havrdova, MD, PhD, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic;
Krzysztof Selmaj, MD, PhD, Medical University of Lodz, Lodz, Poland;
Howard L Weiner, MD, Brigham and Women's Hospital Center for Neurologic Diseases, Boston, MA, USA;
Cary L Twyman, MD, Associates in Neurology PSC, Lexington, KY, USA;
Tamara A Miller, MD, Advanced Neurology of Colorado, Ft Collins, CO, USA;
Stephen L Lake, ScD, Genzyme, Cambridge, MA, USA;
David H Margolin, MD, Genzyme, Cambridge, MA, USA;
Michael A Panzara, MD, Genzyme, Cambridge, MA, USA;
Alastair Compston, MD, University of Cambridge, Cambridge, UK
Patient-Reported Experience Measures and Outcomes in Multiple Sclerosis
Nikki Embrey, RN MSCN MSc, University Hospital, North Staffordshire, NHS Trust, UKMSSNA, IOMSN;
Delyth Thomas, RGN MSCN, Wye Valley NHS Trust, UKMSSNA, IOMSN;
Laura Parkes, BSc (Hons) PhD, Merck Serono Ltd
Treatment Satisfaction and Clinical Improvement After Switch to Fingolimod
Edward Fox, MD, PhD, MS Clinic of Central Texas;
Keith Edwards, MD, FAAN, MS Center of NE New York;
J. Gordon Burch, MD, FRCP(C), FAAN, Blue Ridge Research Center;
Edward Kim, MD, MBA, Novartis Pharmaceuticals Corporation;
Linda Pestreich, BSc, Novartis Pharmaceuticals Corporation;
Kevin McCague, MA, Novartis Pharmaceuticals Corporation;
Luigi M Barbato, MD, Novartis Pharmaceuticals Corporation
First Case of Immune Thrombocytopenia in the CAMPATH Extension Trial (CAMMS03409)
Malcolm H Gottesman, MD, Winthrop University Hospital;
Shicong Ye, MD, Winthrop University Hospital;
John Delmonte Jr., MD, The Saratoga Hospital;
Abigail Mcnall, FNP, Winthrop University Hospital;
Kimberly Byrnes, CCRC, Winthrop University Hospital;
Eileen Boylan, RN, Winthrop University Hospital;
Denise Cheng, RN, Winthrop University Hospital
Data Management and Montitoring in the CombiRx Randomized Trial
Tarah Gustafson, BSN, Corinne Goldsmith Dickinson Center for Multiple Sclerosis;
C. Steve Powell, PhD, University of Alabama at Birmingham;
Amber Salter, MPH, University of Alabama at Birmingham;
Jing Wang, MS, University of Alabama at Birmingham;
Fred D. Lublin, MD, Corinne Goldsmith Dickinson Center for Multiple Sclerosis;
Jerry Wolinsky, MD, University of Texas Health Science Center;
Robin Conwit, MD, NIH;
Gary Cutter, PhD, University of Alabama at Birmingham;
Stacey S Cofield, PhD, University of Alabama at Birmingham
Cardiac Effects of Fingolimod in Patients with Multiple Sclerosis
Bruce L Hughes, MD, Ruan Multiple Sclerosis Center;
Mark Cascione, MD, Tampa Neurology Associates;
Kevin McCague, MA, Novartis Pharmaceuticals Corporation;
Linda Pestreich, BSc, Novartis Pharmaceuticals Corporation;
Lesley Schofield, PhD, Novartis Pharmaceuticals Corporation;
Edward Kim, MD, MBA, Novartis Pharmaceuticals Corporation;
Luigi M Barbato, MD, Novartis Pharmaceuticals Corporation
Effect of Fingolimod on Brain Atrophy: MRI Data From Phase 3 Studies
Douglas Jeffery, MD, PhD, Cornerstone Healthcare;
Jeffrey A Cohen, MD, Cleveland Clinic, Cleveland, OH, USA;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Ron Hashmonay, MD, Novartis Pharmaceuticals Corporation
Durable Effects of Alemtuzumab on Relapse Rate Over Time in CARE-MS II
Lily Jung Henson, MD, Swedish Issaquah, Issaquah, WA, USA;
Douglas L Arnold, MD, Montreal Neurological Institute, McGill University, and NeuroRx Research, Montreal, Quebec, Canada;
Jeffrey A Cohen, MD, Cleveland Clinic, Cleveland, OH, USA;
Alasdair J Coles, MD, University of Cambridge, Cambridge, UK;
Christian Confavreux, MD, University Claude Bernard, Lyon, France;
Edward J Fox, MD, MS Clinic of Central Texas, Round Rock, TX, USA;
Hans-Peter Hartung, MD, Heinrich-Heine University, Dusseldorf, Germany;
Eva Havrdova, MD, PhD, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic;
Krzysztof Selmaj, MD, PhD, Medical University of Lodz, Lodz, Poland;
Howard L Weiner, MD, Brigham and Women's Hospital Center for Neurologic Diseases, Boston, MA, USA;
Tamara A Miller, MD, Advanced Neurology of Colorado, Ft Collins, CO, USA;
Cary L Twyman, MD, Associates in Neurology PSC, Lexington, KY, USA;
Stephen L Lake, ScD, Genzyme, Cambridge, MA, USA;
David H Margolin, MD, Genzyme, Cambridge, MA, USA;
Michael A Panzara, MD, Genzyme, Cambridge, MA, USA;
Alastair Compston, MD, University of Cambridge, Cambridge, UK
Pregnancy Outcomes with Teriflunomide: Female Patients and Partners of Male Patients
Lily Jung Henson, MD, Swedish Medical Center;
Olaf Stuve, MD, University of Texas Southwestern Medical Center at Dallas;
Myriam Benamor, MD, Sanofi;
Sandrine Turpault, PharmD, Sanofi;
Françoise Menguy-Vacheron, PhD, Sanofi
Timecourse of Treatment Effects of BG-12 (Dimethyl Fumarate) in MS
Ludwig Kappos, MD, University Hospital, Basel Neurology, Basel, Switzerland;
Gavin Giovannoni, PhD, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK;
Ralf Gold, MD, Ruhr University, Bochum, Germany;
J. Theodore Phillips, MD PhD FAAN, Baylor Institute for Immunology Research, Dallas, TX, USA;
Christophe Hotermans, MD, PhD, Weston, MA, USA;
Annie Zhang, BM, MPH, Weston, MA, USA;
Vissia Viglietta, MD, Weston, MA, USA;
Robert J. Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic
Efficacy of Glatiramer Acetate 40-mg Injection Three Times Weekly
Omar Khan, MD, Wayne State University;
Peter Reckmann, MD, FRCPC, University of Erlangen;
Alexey Boyko, MD, Moscow MS Center at RSMU, Moscow, Russia;
Krzysztof Selmaj, MD, PhD, Medical University of Lodz, Lodz, Poland;
Robert Zvadinov, MD, PhD, SUNY Buffalo
Patient Reported Outcomes in Primary Progressive Multiple Sclerosis
Grace E Little, BA, Brigham and Women's Hospital;
Kesav Raghavan, BS, Brigham and Women's Hospital;
Brian C Healy, PhD, Massachusetts General Hospital;
David J Rintell, EdD, Brigham and Women's Hospital;
Howard L Weiner, MD, Brigham and Women's Hospital Center for Neurologic Diseases, Boston, MA, USA;
Tanuja Chitnis, MD, Brigham and Women's Hospital;
Bonnie I Glanz, PhD, Brigham and Women's Hospital
CCSVI Treatment and Comorbidity: A Province-Wide Study of Multiple Sclerosis
Ruth Ann Marrie, MD, PhD, FRCPC, University of Manitoba;
Luanne Metz, MD, FRCPC, University of Calgary;
Katayoun Alikhani, MD, University of Calgary;
Gregg Blevins, MD, University of Alberta;
Jacqueline Bakker, MD, University of Calgary;
Larry Svenson, BSc, University of Calgary;
Nathalie Jette, MD, MSc, University of Calgary;
Oksana Suchowersky, MD, University of Alberta;
Mary Louise Myles, MD, University of Alberta;
Winona Wall, BSc, University of Calgary;
James Newsome, BSc, University of Calgary;
Jamie Greenfield, MSc, University of Calgary;
Marcus Koch, MD, PhD, University of Calgary;
Scott Patten, MD, PhD, University of Calgary;
Scott Kraft, MD, MSc, University of Calgary;
Derek Emery, MD, MSc, University of Alberta;
Mayank Goyal, MD, University of Calgary
Combination Interferon-Beta 1a and Mycophenolate Mofetil in RRMS
Jacqueline A Nicholas, MD, The Ohio State University Wexner Medical Center;
Yuhong Yang, MD, The Ohio State University Wexner Medical Center;
Caroline Schaffer, -, The Ohio State University Wexner Medical Center;
Morgan Savel, BS, The Ohio State University Wexner Medical Center;
Kyle Porter, M.A.S., The Ohio State University;
Claudia Kirsch, MD, The Ohio State University Wexner Medical Center;
Michael K Racke, MD, The Ohio State University Wexner Medical Center;
Aaron Boster, MD, The Ohio State University Wexner Medical Center;
Kottil Rammohan, MD, University of Miami
Implementation of a Quality Improvement Program in An MS Clinic
Margie O'Leary, RN, MSN, MSCN, University of Pittsburgh Medical Center;
Rock Heyman, MD, University of Pittsburgh Medical Center;
Ryan Orie, MPAS, PA-C, University of Pittsburgh Medical Center;
Galen Mitchell, MD, University of Pittsburgh Medical Center;
Islam Zaydan, MD, University of Pittsburgh Medical Center;
Rebecca Rosiek, RN, BSN, University of Pittsburgh Medical Center;
Victoria Young, RN, BSN, University of Pittsburgh Medical Center;
Kerry Oddis, RN, University of Pittsburgh Medical Center;
Darlene Punjack, RMA, University of Pittsburgh Medical Center
Effect of BG-12 (Dimethyl Fumarate) in Newly Diagnosed Relapsing Remitting MS Patients
J. Theodore Phillips, MD PhD FAAN, Baylor Institute for Immunology Research, Dallas, TX, USA;
Ralf Gold, MD, Ruhr University, Bochum, Germany;
Gavin Giovannoni, PhD, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK;
Robert J. Fox, MD, FAAN, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic;
Annie Zhang, BM, MPH, Weston, MA, USA;
Leslie Meltzer, PhD, Weston, MA, USA;
Nuwan C Kurukulasuriya, PhD, Weston, MA, USA
JCV Antibody Index Stratifies PML Risk in Natalizumab-Treated MS Patients
Tatiana Plavina, PhD, Biogen Idec Inc.;
Meena Subramanyam, PhD, Biogen Idec Inc.;
Gary Bloomgren, MD, Biogen Idec Inc.;
Sandra Richman, MD, MPH, Biogen Idec Inc.;
Amy Pace, ScD, Biogen Idec Inc.;
Sophia Lee, PhD, Biogen Idec Inc.;
Brian Schlain, MS, Biogen Idec Inc.;
Denise Campagnolo, MD, Biogen Idec Inc.;
Barry Ticho, MD, PhD, Biogen Idec Inc.
BG-12 (Dimethyl Fumarate) with Aspirin Pretreatment or Slow Dose Titration
Heidy Russell, PhD, PROMETRIKA, LLC, Cambridge, MA, USA;
John O'Gorman, PhD, Biogen Idec Inc., Weston, MA, USA;
Jie Li, MD, MS, Biogen Idec Inc., Weston, MA, USA;
Glenn Phillips, PhD, Biogen Idec Inc., Weston, MA, USA;
Vissia Viglietta, MD, Weston, MA, USA
Predictors of Switching First-Line Disease-Modifying Therapy for MS Patients
Barbara E. Teter, PhD, MPH, State University of New York at Buffalo;
Neetu Agashivala, MS, Novartis Pharmaceuticals Corporation;
Katelyn S. Kavak, MS, University at Buffalo;
Lynn Chouhfeh, MD, University at Buffalo;
Ron Hashmonay, MD, Novartis Pharmaceuticals Corporation;
Bianca Weinstock-Guttman, MD, State University of New York at Buffalo
Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire: Pilot Study
Alona Williamson, RN, Neurology Center of Fairfax;
Tracy Flemming Tracy, OT, MSCS, Tanner Center and Foundation for MS;
Jennifer Smrtka, MSN, ANP-C, MSCN, South Florida Neurology Associates;
Carol Saunders, BSN, BA, MSCN, Neurology Center;
Constance B Easterling, RN, MSN, ANP, MSCN, Multiple Sclerosis Care Center of Neurological Services;
Amy Perrin Ross, APN, MSN, CNRN, MSCN, Loyola University Chicago;
John Niewoehner, PharmD, Questcor Pharmaceuticals;
Nicole Mutschler, PhD, Questcor Pharmaceuticals
Herpes Infection Risk Reduced with Acyclovir Prophylaxis After Alemtuzumab
Sibyl E Wray, MD, Hope Neurology, Knoxville, TN, USA;
Douglas L Arnold, MD, Montreal Neurological Institute, McGill University, and NeuroRx Research, Montreal, Quebec, Canada;
Jeffrey A Cohen, MD, Cleveland Clinic, Cleveland, OH, USA;
Alasdair J Coles, MD, University of Cambridge, Cambridge, UK;
Christian Confavreux, MD, University Claude Bernard, Lyon, France;
Edward J Fox, MD, MS Clinic of Central Texas, Round Rock, TX, USA;
Hans-Peter Hartung, MD, Heinrich-Heine University, Dusseldorf, Germany;
Eva Havrdova, MD, PhD, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic;
Krzysztof Selmaj, MD, PhD, Medical University of Lodz, Lodz, Poland;
Howard L Weiner, MD, Brigham and Women's Hospital Center for Neurologic Diseases, Boston, MA, USA;
Tamara A Miller, MD, Advanced Neurology of Colorado, Ft Collins, CO, USA;
Cary L Twyman, MD, Associates in Neurology PSC, Lexington, KY, USA;
Stephen L Lake, ScD, Genzyme, Cambridge, MA, USA;
David H Margolin, MD, Genzyme, Cambridge, MA, USA;
Michael A Panzara, MD, Genzyme, Cambridge, MA, USA;
Alastair Compston, MD, University of Cambridge, Cambridge, UK
High Monthly T2 Lesion Burden Associated with Improved EDSS Upon Starting MS Treatment
Charles C Yu, BA, Case Western Reserve University School of Medicine;
Samantha Lancia, MS, Washington University in St. Louis School of Medicine;
Nhial Tutlam, MPH, Washington University in St. Louis School of Medicine;
Junqian Xu, PhD, Mount Sinai School of Medicine;
Robert T Naismith, MD, Washington University in St. Louis School of Medicine
![[ Visit Client Website ]](images/banner.gif)